Menu
Oslo, Norway, 20 December 2024: Reference is made to the stock exchange announcements by Thor Medical ASA (the "Company") on 20 December 2024 regarding the registration of share capital increase following the private placement of new shares by the Company (the "Private Placement") and the retail offering of new shares (the "PrimaryBid Offering").
Roth Invest AS holds 11,794,640 shares in the Company, representing approx. 5.02 % of the issued share capital and votes prior to the Private Placement and the PrimaryBid Offering.
Following the registration of share capital increase resulting from shares issued in tranche 1 of the Private Placement and the shares issued in the PrimaryBid Offering, Roth Invest AS shareholding in the Company represents approx. 4.2% of the 280,492,395 issued shares and votes in the Company and has fallen below the 5%.
Contacts
Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.
To learn more, visit www.thormedical.no - https://www.thormedical.no.
